Curated News
By: NewsRamp Editorial Staff
January 20, 2026
Kairos Pharma to Showcase Oncology Pipeline at 2026 Investor Conference
TLDR
- Kairos Pharma's investor presentation at the DealFlow Discovery Conference offers potential early insights into their oncology pipeline for competitive investment advantage.
- Kairos Pharma will present clinical-stage oncology programs at the DealFlow Discovery Conference, detailing their structural biology approach to overcoming cancer drug resistance.
- Kairos Pharma's clinical trials for ENV-105 aim to improve cancer treatment outcomes by addressing drug resistance and disease relapse in patients.
- Kairos Pharma's lead candidate ENV-105 targets CD105 to reverse drug resistance in cancers like prostate and lung cancer during clinical trials.
Impact - Why it Matters
This news matters because it highlights the ongoing development of novel cancer therapies that could address critical challenges in treatment, such as drug resistance and disease relapse. For patients with conditions like castrate-resistant prostate cancer and non-small cell lung cancer, where current options may be limited, advancements like ENV-105 offer hope for more effective treatments. From an investment perspective, it signals Kairos Pharma's active engagement with the financial community, potentially influencing stock performance and funding for further research. Additionally, the use of platforms like TinyGems underscores the importance of strategic communication in raising awareness and support for emerging biotech companies, which can accelerate innovation and bring new therapies to market faster.
Summary
Kairos Pharma Ltd. (NYSE American: KAPA), a Los Angeles-based clinical-stage oncology company, has announced its participation in the upcoming DealFlow Discovery Conference scheduled for January 28–29, 2026, at the Borgata Hotel, Casino & Spa in Atlantic City, New Jersey. The company's Chief Scientific Officer, Neil Bhowmick, will deliver a presentation and engage in one-on-one meetings with investors, highlighting the company's progress in advancing its innovative cancer therapies. This strategic move underscores Kairos Pharma's commitment to raising its profile within the investment community as it continues to develop its promising pipeline.
At the core of Kairos Pharma's efforts is its lead candidate, ENV-105, an antibody designed to target the CD105 protein, which is implicated in drug resistance and disease relapse in various cancers. The company leverages structural biology to overcome immune suppression and resistance mechanisms, aiming to restore the efficacy of standard treatments. ENV-105 is currently undergoing clinical trials, including a Phase 2 study for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, addressing significant unmet medical needs in oncology. It is important to note that ENV-105 has not yet received approval from the U.S. Food and Drug Administration or comparable international regulators.
The news release was distributed through TinyGems, a specialized communications platform focused on innovative small-cap and mid-cap companies, which is part of the broader Investor Brand Network (IBN). TinyGems provides services such as press release enhancement, social media distribution, and access to a vast network of syndication partners, ensuring maximum reach for its clients. For more details, readers can view the full press release via the provided hyperlink. This announcement not only highlights Kairos Pharma's ongoing clinical advancements but also emphasizes the role of platforms like TinyGems in amplifying corporate communications within the financial and investment sectors.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Kairos Pharma to Showcase Oncology Pipeline at 2026 Investor Conference
